Michael Rod Zalutsky

Bio

The overall objective of our laboratory is the development of novel radioactive compounds for improving the diagnosis and treatment of cancer. This work primarily involves radiohalo-genation of biomolecules via site-specific approaches, generally via demetallation reactions. Radionuclides utilized for imaging include I-123, I-124 and F-18, the later two being of particular interest because they can be used for the quantification of biochemical and physiological processes in the living human through positron emission tomography. For therapy, astatine-211 decays by the emission of alpha-particles, a type of radiation considerably more cytotoxic that the beta-particles used in conventional endoradiotherapy. The range of At-211 alpha particles is only a few cell diameters, offering the possibility of extremely focal irradiation of malignant cells while leaving neighboring cells intact. Highlights of recent work include: a)
development of reagents for protein and peptide radioiodination that decrease deiodination in vivo by up to 100-fold, b) demonstration that At-211 labeled monoclonal antibodies are effective in the treatment of a rat model of neoplastic meningitis, c) synthesis of a thymidine analogue labeled with At-211 and the demonstration that this molecule is taken up in cellular DNA with highly cytotoxicity even at levels of only one atom bound per cell and d) development of
radiohalobenzylguanidines which are specifically cytotoxic for human neuroblastoma cells.

Education

• M.A. Washington University in St. Louis, 1972
• Ph.D. Washington University in St. Louis, 1974

Positions

• Jonathan Spicehandler, M.D. Distinguished Professor of Neuro Oncology, in the School of Medicine
• Professor of Radiology
• Professor of Biomedical Engineering
• Professor in Pathology
• Professor of Radiation Oncology
• Member of the Duke Cancer Institute

Awards, Honors, and Distinctions

• Aebersold Award. Socienty of Nuclear Medicine. 2007
• MERIT Award. National Institutes of Health. 2005

Publications

• Feng Y, Meshaw RL, Finch SW, Zheng Y, Minn I, Vaidyanathan G, et al. A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation. Nucl Med Biol. 2024;134–135:108916.
• Huynh TT, Feng Y, Meshaw R, Zhao X-G, Rosenfeld L, Vaidyanathan G, et al. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics. Nucl Med Biol. 2024;134–135:108913.
• Obata H, Ogawa M, Zalutsky MR. DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy. Pharmaceutics. 2023 Jul 11;15(7).
• Feng Y, Meshaw R, Zhao X-G, Jannetti S, Vaidyanathan G, Zalutsky MR. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment. J Nucl Med. 2023 Jan;64(1):124–30.
• Vaidyanathan G, Feng Y, Zalutsky MR. The Radiopharmaceutical Chemistry of the Halogen Radionuclides. In: Radiopharmaceutical Therapy. 2023. p. 145–72.
• Rowe SP, Werner RA, Garg T, Gafita A, Voter AF, Sadaghiani MS, et al. Small Molecules as Vectors for Radiopharmaceutical Therapy. In: Radiopharmaceutical Therapy. 2023. p. 349–67.
• Feng Y, Sarrett SM, Meshaw RL, Vaidyanathan G, Cornejo MA, Zeglis BM, et al. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent. J Med Chem. 2022 Nov 24;65(22):15358–73.
• Schaal JL, Bhattacharyya J, Brownstein J, Strickland KC, Kelly G, Saha S, et al. Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours. Nat Biomed Eng. 2022 Oct;6(10):1148–66.
• Zhou Z, Zalutsky MR, Chitneni SK. Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model. Bioorg Med Chem Lett. 2022 Jun 15;66:128725.
• Feng Y, Meshaw R, McDougald D, Zhou Z, Zhao X-G, Jannetti SA, et al. Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers. Sci Rep. 2022 Feb 22;12(1):3020.
• Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, et al. An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy. J Nucl Med. 2022 Feb;63(2):259–67.
• Procissi D, Jannetti SA, Zannikou M, Zhou Z, McDougald D, Kanojia D, et al. Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases. Neurooncol Adv. 2022;4(1):vdac135.
• Zhou Z, Meshaw R, Zalutsky MR, Vaidyanathan G. Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment. J Nucl Med. 2021 Nov;62(11):1624–30.
• Zhou Z, Zalutsky MR, Chitneni SK. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. Mol Pharm. 2021 Oct 4;18(10):3871–81.
• Chitneni SK, Zhou Z, Watts BE, Zalutsky MR. Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141. Pharmaceuticals (Basel). 2021 Apr 13;14(4).
• Liu Y, Zhou Z, Feng Y, Zhao X-G, Vaidyanathan G, Zalutsky MR, et al. Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy. Int J Nanomedicine. 2021;16:7297–305.
• Vaidyanathan G, Mease RC, Minn I, Choi J, Chen Y, Shallal H, et al. Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer. Nucl Med Biol. 2021;94–95:67–80.
• Feng Y, Zhou Z, McDougald D, Meshaw RL, Vaidyanathan G, Zalutsky MR. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent. Nucl Med Biol. 2021 Jan;92:171–83.
• Zhou Z, McDougald D, Meshaw R, Balyasnikova I, Zalutsky MR, Vaidyanathan G. Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate. Nucl Med Biol. 2021;100–101:24–35.
• Liu Y, Zhou Z, Feng Y, Zhao X-G, Vaidyanathan G, Zalutsky MR, et al. Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy. INTERNATIONAL JOURNAL OF NANOMEDICINE. 2021;16:7297–305.
• Feng Y, Zalutsky MR. Production, purification and availability of 211At: Near term steps towards global access. Nucl Med Biol. 2021;100–101:12–23.
• Babak MV, Zalutsky MR, Balyasnikova IV. Heterogeneity and vascular permeability of breast cancer brain metastases. Cancer Lett. 2020 Oct 1;489:174–81.
• Zhou Z, Zalutsky MR, Vaidyanathan G. Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative. Bioorg Med Chem. 2020 Sep 1;28(17):115634.
• Vaidyanathan G, Pozzi OR, Choi J, Zhao X-G, Murphy S, Zalutsky MR. Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor. Cancer Biother Radiopharm. 2020 Sep;35(7):511–9.
• Jannetti SA, Zeglis BM, Zalutsky MR, Reiner T. Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. Front Pharmacol. 2020;11:170.
• Rosenkranz AA, Slastnikova TA, Georgiev GP, Zalutsky MR, Sobolev AS. Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters. Nucl Med Biol. 2020;80–81:45–56.
• Chitneni SK, Koumarianou E, Vaidyanathan G, Zalutsky MR. Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab. Molecules. 2019 Oct 30;24(21).
• Liu Y, Carpenter AB, Pirozzi CJ, Yuan H, Waitkus MS, Zhou Z, et al. Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe. Nanotechnology. 2019 Jul 5;30(27):275101.
• Zhou Z, McDougald D, Devoogdt N, Zalutsky MR, Vaidyanathan G. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. Mol Pharm. 2019 Jan 7;16(1):214–26.
• Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, et al. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. PLoS One. 2019;14(5):e0216934.
• Vaidyanathan G, Zalutsky MR. The Radiopharmaceutical Chemistry of the Radioisotopes of Iodine. In: Radiopharmaceutical Chemistry. 2019. p. 391–408.
• Zhou Z, Devoogdt N, Zalutsky MR, Vaidyanathan G. An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker. Bioconjug Chem. 2018 Dec 19;29(12):4090–103.
• Chitneni SK, Yan H, Zalutsky MR. Synthesis and Evaluation of a 18F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. ACS Med Chem Lett. 2018 Jul 12;9(7):606–11.
• Pruszynski M, Kang CM, Koumarianou E, Vaidyanathan G, Zalutsky MR. d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution. Molecules. 2018 May 20;23(5).
• Zhou Z, Chitneni SK, Devoogdt N, Zalutsky MR, Vaidyanathan G. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. Bioorg Med Chem. 2018 May 1;26(8):1939–49.
• Chitneni SK, Reitman ZJ, Spicehandler R, Gooden DM, Yan H, Zalutsky MR. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorg Med Chem Lett. 2018 Feb 15;28(4):694–9.
• Choi J, Vaidyanathan G, Koumarianou E, Kang CM, Zalutsky MR. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. Nucl Med Biol. 2018 Jan;56:10–20.
• Vaidyanathan G, Kang CM, McDougald D, Minn I, Brummet M, Pomper MG, et al. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Nucl Med Biol. 2018;62–63:18–30.
• Zhou Z, Vaidyanathan G, McDougald D, Kang CM, Balyasnikova I, Devoogdt N, et al. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. Mol Imaging Biol. 2017 Dec;19(6):867–77.
• D’Huyvetter M, De Vos J, Xavier C, Pruszynski M, Sterckx YGJ, Massa S, et al. 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. Clin Cancer Res. 2017 Nov 1;23(21):6616–28.
• Raghavan R, Howell RW, Zalutsky MR. A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers. Biomed Phys Eng Express. 2017 Jun;3(3).
• Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles. Nucl Med Biol. 2017 Mar;46:43–9.
• Chin BB, McDougald D, Weitzel DH, Hawk T, Reiman RE, Zalutsky MR, et al. Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine. Curr Radiopharm. 2017;10(1):41–50.
• Slastnikova TA, Rosenkranz AA, Morozova NB, Vorontsova MS, Petriev VM, Lupanova TN, et al. Preparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransporters. Int J Nanomedicine. 2017;12:395–410.
• Rowe SP, Drzezga A, Neumaier B, Dietlein M, Gorin MA, Zalutsky MR, et al. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. J Nucl Med. 2016 Oct;57(Suppl 3):90S-96S.
• Vaidyanathan GV, Zhou Z, McDougald D, Lahoutte T, Zalutsky MR. Anti-HER2 Single Domain Antibody 2Rs15d Labeled with F-18 Using a Residualizing Label: Preliminary Evaluation. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER; 2016. p. S179–S179.
• Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. J Nucl Med. 2016 Oct;57(10):1569–75.
• Chitneni SK, Reitman ZJ, Gooden DM, Yan H, Zalutsky MR. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. Eur J Med Chem. 2016 Aug 25;119:218–30.
• Vaidyanathan G, McDougald D, Choi J, Koumarianou E, Weitzel D, Osada T, et al. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. J Nucl Med. 2016 Jun;57(6):967–73.
• Schaal JL, Li X, Mastria E, Bhattacharyya J, Zalutsky MR, Chilkoti A, et al. Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. J Control Release. 2016 Apr 28;228:58–66.
• Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, et al. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Invest New Drugs. 2016 Apr;34(2):149–58.
• Mukerji R, Schaal J, Li X, Bhattacharyya J, Asai D, Zalutsky MR, et al. Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor. Biomaterials. 2016 Feb;79:79–87.
• Vaidyanathan G, McDougald D, Choi J, Pruszynski M, Koumarianou E, Zhou Z, et al. N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules. Org Biomol Chem. 2016 Jan 28;14(4):1261–71.
• Chin BB, McDougald D, Weitzel D, Hawk T, Reiman RE, Zalutsky MR, et al. Synthesis and preliminary evaluation of 5-[18F]fluoroleucine: a novel LAT1 substrate (In preparation). Current Radiopharmaceuticals. 2016;
• Vaidyanathan G, McDougald D, Choi J, Koumarianou E, Pruszynski M, Osada T, et al. An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER; 2015. p. S102–S102.
• Vaidyanathan G, McDougald D, Koumarianou E, Choi J, Hens M, Zalutsky MR. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. Nucl Med Biol. 2015 Aug;42(8):673–84.
• Schaal JL, Liu W, Chilkoti A, Li X, Mastria E, Zalutsky MR. Abstract 1809: Next-generation brachytherapy: a preclinical study of a thermally stabilized biopolymer gel for delivering intratumoral radionuclide therapy in a pancreatic tumor mouse model. In: Cancer Research. American Association for Cancer Research (AACR); 2015. p. 1809–1809.
• Pruszyński M, Łyczko M, Bilewicz A, Zalutsky MR. Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. Nucl Med Biol. 2015 May;42(5):439–45.
• Chitneni SK, Bida GT, Zalutsky MR, Dewhirst MW. Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding. J Nucl Med. 2015 Apr;56(4):653–4.
• Pruszynski M, Koumarianou E, Vaidyanathan G, Chitneni S, Zalutsky MR. D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. Nucl Med Biol. 2015 Jan;42(1):19–27.
• Slastnikova TA, Rosenkranz AA, Zalutsky MR, Sobolev AS. Modular nanotransporters for targeted intracellular delivery of drugs: Folate receptors as potential targets. Current Pharmaceutical Design. 2015;21(9):1227–38.
• Liu Y, Ashton JR, Moding EJ, Yuan H, Register JK, Fales AM, et al. A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy. Theranostics. 2015;5(9):946–60.
• Slastnikova TA, Rosenkranz AA, Zalutsky MR, Sobolev AS. Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. Curr Pharm Des. 2015;21(9):1227–38.
• Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, et al. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014 Oct 15;74(20):5819–31.
• Koumarianou E, Slastnikova TA, Pruszynski M, Rosenkranz AA, Vaidyanathan G, Sobolev AS, et al. Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol. 2014 Jul;41(6):441–9.
• Chitneni SK, Bida GT, Zalutsky MR, Dewhirst MW. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. J Nucl Med. 2014 Jul;55(7):1192–7.
• Pruszynski M, Koumarianou E, Vaidyanathan G, Revets H, Devoogdt N, Lahoutte T, et al. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med. 2014 Apr;55(4):650–6.
• Choi J, Vaidyanathan G, Koumarianou E, McDougald D, Pruszynski M, Osada T, et al. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. Nucl Med Biol. 2014;41(10):802–12.
• Barrott JJ, Smith AP, Osada T, Ramanujam N, Zalutsky MR, Lyerly K, et al. Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. In: Molecular Cancer Therapeutics. American Association for Cancer Research (AACR); 2013. p. C86–C86.
• Barrott JJ, Hughes PF, Osada T, Yang X-Y, Hartman ZC, Loiselle DR, et al. Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. Chem Biol. 2013 Sep 19;20(9):1187–97.
• Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, et al. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. J Nucl Med. 2013 Aug;54(8):1339–46.
• Sobolev AS, Rosenkranz AA, Zalutsky MR. Modular nanotransporters: a versatile platform for nuclear delivery of anti-cancer pharmaceuticals. In: FEBS JOURNAL. WILEY-BLACKWELL; 2013. p. 376–376.
• Choi J, Vaidyanathan G, Koumarianou E, Pruszynski M, Lahoutte T, Zalutsky MR. Isomeric N-succinimidyl 3-guanidinomethyl-5-[I-131]iodobenzoate (iso-[I-131]SGMIB): A guanidine-containing residualizing agent for radiohalogenation of internalizing biomolecules. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2013 May 1;56:S39–S39.
• Vaidyanathan G, McDougald D, Pruszynski M, Koumarianou E, Hens MA, Lahoutte T, et al. SFBTMGMB (N-succinimidyl 3-((4-(4-fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate): An SGMIB analogue for labeling internalizing biomolecules with F-18. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2013 May 1;56:S127–S127.
• Liu W, McDaniel JR, Li X, Schaal J, Bhattacharyya J, Zalutsky MR, et al. Abstract 4341: A novel injectable polymer liquid that self-assembles into radioactive “seeds” for brachytherapy. In: Cancer Research. American Association for Cancer Research (AACR); 2013. p. 4341–4341.
• Pruszynski M, Koumarianou E, Vaidyanathan G, Revets H, Devoogdt N, Lahoutte T, et al. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol. 2013 Jan;40(1):52–9.
• Vaidyanathan G, White BJ, Affleck DJ, Zhao XG, Welsh PC, McDougald D, et al. SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. Bioorg Med Chem. 2012 Dec 15;20(24):6929–39.
• Liu W, McDaniel J, Li X, Asai D, Quiroz FG, Schaal J, et al. Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ. Cancer Res. 2012 Nov 15;72(22):5956–65.
• Slastnikova TA, Koumarianou E, Rosenkranz AA, Vaidyanathan G, Lupanova TN, Sobolev AS, et al. Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I. EJNMMI Res. 2012 Oct 29;2(1):59.
• Chitneni SK, Bida GT, Dewhirst MW, Zalutsky MR. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). Nucl Med Biol. 2012 Oct;39(7):1012–8.
• Asai D, Xu D, Liu W, Garcia Quiroz F, Callahan DJ, Zalutsky MR, et al. Protein polymer hydrogels by in situ, rapid and reversible self-gelation. Biomaterials. 2012 Jul;33(21):5451–8.
• Liu W, McDaniel JR, Li X, Asai D, Zalutsky MR, Chilkoti A. Abstract 2884: Preclinical studies on tumor retention, antitumor efficacy and toxicity of thermally responsive polypeptide-based radionuclide intratumoral depot in nude mice. Cancer Research. 2012 Apr 15;72(8_Supplement):2884–2884.
• Zalutsky MR, Vaidyanathan G. TARGETED ALPHA THERAPY. In: RADIOTHERAPY AND ONCOLOGY. ELSEVIER IRELAND LTD; 2012. p. S195–S195.
• Zalutsky MR, Boskovitz A, Kuan C-T, Pegram CN, Ayriss J, Wikstrand CJ, et al. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol. 2012 Jan;39(1):23–34.
• Slastnikova TA, Rosenkranz AA, Gulak PV, Schiffelers RM, Lupanova TN, Khramtsov YV, et al. Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. Int J Nanomedicine. 2012;7:467–82.
• Vaidyanathan G, McDougald D, Grasfeder L, Zalutsky MR, Chin B. An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine. Appl Radiat Isot. 2011 Oct;69(10):1401–6.
• Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharm. 2011 Oct;4(4):283–94.
• Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, et al. Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 2011 Sep;69(3):668–76.
• Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm. 2011 Jul;4(3):177–85.
• Vaidyanathan G, Li J, Bigner DD, Zalutsky MR. TARGETED RADIOTHERAPY OF MEDULLOBLASTOMA USING SOMATOSTATIN RECEPTOR AVID RADIOLABELED PEPTIDES. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2011. p. I27–I27.
• Chitneni SK, Bida GT, Hay MP, Zalutsky MR, Melcher T, Wilson WR, et al. Abstract 5306: 18F-EF5 microPET imaging of treatment response from a novel, hypoxia-selective cytotoxin SN30000 in a human lung cancer xenograft model. Cancer Research. 2011 Apr 15;71(8_Supplement):5306–5306.
• Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. J Nucl Med. 2011 Feb;52(2):165–8.
• Vaidyanathan G, Zalutsky MR. Applications of ²¹¹AT and ²²³RA in targeted alpha-particle radiotherapy. Current Radiopharmaceuticals. 2011;4(4):283–94.
• Vaidyanathan G, White B, Affleck DJ, McDougald D, Zalutsky MR. Radioiodinated O(6)-Benzylguanine derivatives containing an azido function. Nucl Med Biol. 2011 Jan;38(1):77–92.
• Vaidyanathan G, McDougald D, Affleck DJ, Zalutsky MR. A tin precursor of SGMIB potentially useful in the direct modification of peptides and proteins before radiohalogenation. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2011 Jan 1;54:S64–S64.
• Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, et al. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol. 2010 Oct;37(7):785–94.
• Hens M, Vaidyanathan G, Zhao X-G, Bigner DD, Zalutsky MR. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol. 2010 Oct;37(7):741–50.
• Vaidyanathan G, White B, Affleck DJ, McDougald D, Zalutsky MR. Radioiodinated O6-Benzylguanine Analogues Containing an Azido Function. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER; 2010. p. S265–S265.
• Gao W, Liu W, Christensen T, Zalutsky MR, Chilkoti A. In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16432–7.
• Kuan C-T, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer. 2010 Aug 1;127(3):598–611.
• Zalutsky MR, Reardon DA, Bigner DD. Targeted Radiotherapy of Central Nervous System Malignancies. 2010 Jul 15;139–67.
• Liu W, MacKay JA, Dreher MR, Chen M, McDaniel JR, Simnick AJ, et al. Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model. J Control Release. 2010 May 21;144(1):2–9.
• Vaidyanathan G, Affleck DJ, Zhao X-G, Keir ST, Zalutsky MR. [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma. Curr Radiopharm. 2010;3(1):29–36.
• Kuan C-T, Wikstrand CJ, McLendon RE, Zalutsky MR, Kumar U, Bigner DD. Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. Hybridoma (Larchmt). 2009 Dec;28(6):389–403.
• Vaidyanathan G, Song H, Affleck D, McDougald DL, Storms RW, Zalutsky MR, et al. Targeting aldehyde dehydrogenase: a potential approach for cell labeling. Nucl Med Biol. 2009 Nov;36(8):919–29.
• Gao W, Liu W, Mackay JA, Zalutsky MR, Toone EJ, Chilkoti A. In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics. Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15231–6.
• Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nucl Med Biol. 2009 Aug;36(6):659–69.
• Vaidyanathan G, Jestin E, Olafsen T, Wu AM, Zalutsky MR. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. Nucl Med Biol. 2009 Aug;36(6):671–80.
• Kuan C-T, Wakiya K, Herndon JE, Wikstrand CJ, McLendon RE, Zalutsky MR, et al. RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY. NEURO-ONCOLOGY. 2009 Apr 1;11(2):224–224.
• Hens M, Vaidyanathan G, Welsh P, Zalutsky MR. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol. 2009 Feb;36(2):117–28.
• Vaidyanathan G, White BJ, Zalutsky MR. Propargyl 4-[F]fluorobenzoate: A Putatively More Stable Prosthetic group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry. Curr Radiopharm. 2009 Jan 1;2(1):63–74.
• Rosenkranz AA, Vaidyanathan G, Pozzi OR, Lunin VG, Zalutsky MR, Sobolev AS. Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):193–200.
• Vaidyanathan G, Zalutsky MR. Astatine Radiopharmaceuticals: Prospects and Problems. Curr Radiopharm. 2008 Sep 1;1(3):177.
• Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008 Jun;10(3):320–9.
• Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr;10(2):182–9.
• Pruszyński M, Bilewicz A, Zalutsky MR. Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis. Bioconjug Chem. 2008 Apr;19(4):958–65.
• Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008 Jan;49(1):30–8.
• Petrik M, Laznickova A, Laznicek M, Zalutsky MR. Radiolabelling of glucose-Tyr³-octreotate with ¹²⁵I and analysis of its metabolism in rats: Comparison with radiolabelled DOTA-Tyr³-octreotate. Anticancer Research. 2007 Nov 1;27(6 B):3941–6.
• Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007 Oct;34(7):779–85.
• Chin BB, Storms RW, Base K, Lascola C, Haystead T, Zalutsky MR, et al. [I-125] iodoquine uptake in tumor cell lines with high ALDH expression. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER; 2007. p. S222–S222.
• Pruszynski M, Bilewicz A, Zalutsky MR. Synthesis of Rh[16aneS4] At-211 and Ir[16aneS4] At-211 complexes - new prosthetic groups for labelling with astatine. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER; 2007. p. S210–S210.
• Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At. J Nucl Med. 2007 Jul;48(7):1190–6.
• Vaidyanathan G, Affleck DJ, Alston KL, Zhao X-G, Hens M, Hunter DH, et al. A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem. 2007 May 15;15(10):3430–6.
• Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007 May;7(5):675–87.
• McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, et al. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 2007 May;34(4):405–13.
• Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol. 2007 Feb;34(2):173–83.
• Petrik M, Laznickova A, Laznicek M, Zalutsky MR. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate. Anticancer Res. 2007;27(6B):3941–6.
• Vaidyanathan G, Affleck DJ, Norman J, O’Dorisio S, Zalutsky MR. A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells. Bioconjug Chem. 2007;18(6):2122–30.
• Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides. Nat Protoc. 2007;2(2):282–6.
• Vaidyanathan G, Affleck DJ, Alston KL, Zalutsky MR. A tin precursor for the synthesis of no-carrier-added [*I]MIBG and [²¹¹At]MABG. Journal of Labelled Compounds and Radiopharmaceuticals. 2007 Jan 1;50(3):177–82.
• Liu W, Dreher MR, Furgeson DY, Peixoto KV, Yuan H, Zalutsky MR, et al. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release. 2006 Nov 28;116(2):170–8.
• Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA. A thermally responsive biopolymer for intra-articular drug delivery. J Control Release. 2006 Oct 10;115(2):175–82.
• Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, McLendon RE, et al. Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Sep 1;33:S194–S194.
• Laznickova A, Petrik M, Melicharova L, Laznicek M, Zalutsky MR. Preclinical pharmacokinetic comparison of glucose-125I-Tyr3-octreotate with DOTA-125I-Tyr3-octreotate. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Sep 1;33:S307–8.
• Zalutsky MR, Reardon DA, Quinn JA, Coleman RE, Akabani G, Friedman AH, et al. Chimeric murine/human IgG(2) anti-tenascin 81C6 monoclonal antibody: phase I trial in patients with malignant glioma of a construct with improved stability. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Sep 1;33:S194–S194.
• Boskovitz A, Ochiai H, Okamura T, Akabani G, Carlin S, Bigner DD, et al. At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Sep 1;33:S378–S378.
• Boskovitz A, Ochiai H, Okamura T, Akabani G, Carlin S, Bigner DD, et al. At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Sep 1;33:S184–S184.
• Liu W, Dreher MR, Chow DC, Zalutsky MR, Chilkoti A. Tracking the in vivo fate of recombinant polypeptides by isotopic labeling. J Control Release. 2006 Aug 28;114(2):184–92.
• Zalutsky MR. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. J Nucl Med. 2006 Aug;47(8):1238–40.
• Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006 Jun;47(6):912–8.
• Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med. 2006 Jun;47(6):1007–15.
• Dreher MR, Liu W, Zalutsky MR, Dewhirst MW, Chilkoti A. Targeted drug delivery to solid tumors using thermally responsive elastin-like polypeptide macromolecular drug carriers. In: CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2006.
• Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006 Apr;33(3):333–47.
• Zalutsky MR. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1958–60.
• Shankar S, Zalutsky MR, Friedman H, Vaidyanathan G. Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. Nucl Med Biol. 2006 Apr;33(3):399–407.
• Vaidyanathan G, Alston KL, Bigner DD, Zalutsky MR. Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. Bioconjug Chem. 2006;17(4):1085–92.
• Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 1;24(1):115–22.
• Vaidyanathan G, Zalutsky MR. Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins. Nat Protoc. 2006;1(2):707–13.
• Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc. 2006;1(4):1655–61.
• Shankar S, Vaidyanathan G, Kuan C-T, Bigner DD, Zalutsky MR. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol. 2006 Jan;33(1):101–10.
• Vaidyanathan G, Affleck DJ, Schottelius M, Wester H, Friedman HS, Zalutsky MR. Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor. Bioconjug Chem. 2006;17(1):195–203.
• Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D, et al. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Med Chem. 2005 Nov;1(6):611–8.
• Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. J Nucl Med. 2005 Aug;46(8):1393–400.
• Boskovitz A, Pegram C, Peixoto K, Zalutsky MR, Bigner DD. Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 370–370.
• Vaidyanathan G, Alston KL, Welsh PC, Zalutsky MR. Enhanced cellular retention of an internalizing anti-EGFRvIII monoclonal antibody radioiodinated using LYS5-[*I]iodobenzoyl Gly(1)-maleimido GEEEK ([*I]IB-Mal-D-GEEEK), a prosthetic group containing negatively charged D-glutamates. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 386–386.
• Shankar S, Zalutsky MR, Vaidyanathan G. O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT). Bioorg Med Chem. 2005 Jun 2;13(12):3889–98.
• Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 2005 Jun;46(6):1042–51.
• Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles. J Nucl Med. 2005 Apr;46(4):700–6.
• Vaidyanathan G, Base K, Zalutsky MR. 0(6)-{4-(3-[F-18]fluoropropyl)-benzyl}-2 '-deoxyguanosine ([F-18]FPBdG) - Synthesis and evaluation of a potential DNA repair protein 0(6)-alkyguanine-DNA alkyltransferase (AGT) imaging agent. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC; 2005. p. U182–U182.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. Appl Radiat Isot. 2005 Mar;62(3):435–40.
• Hauck ML, Zalutsky MR. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. Int J Hyperthermia. 2005 Feb;21(1):1–11.
• Hauck ML, Zalutsky MR. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. Int J Hyperthermia. 2005 Feb;21(1):13–27.
• Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med. 2005 Jan;46 Suppl 1:151S-156S.
• Vaidyanathan G, Boskovitz A, Shankar S, Zalutsky MR. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides. 2004 Dec;25(12):2087–97.
• Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289–96.
• Yordanov AT, Pozzi O, Carlin S, Akabani G, Wieland B, Zalutsky MR. Wet harvesting of no-carrier-added ²¹¹At from an irradiated ²⁰⁹Bi target for radiopharmaceutical applications. Journal of Radioanalytical and Nuclear Chemistry. 2004 Dec 1;262(3):593–9.
• Boskovitz A, Vaidyanathan G, Archer GE, Ochiai H, Okamura T, Sampson JH, et al. Medulloblastoma neoplastic meningitis targeted radiotherapy with intrathecal alpha-emitter At-211-labeled thymidine analogue. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2004. p. 403–403.
• Kuan CT, Wikstrand CJ, Davis TS, Zalutsky MR, Bigner DD. Monoclonal antibodies (MABS) against somatostatin receptor 2A (SSTR2A) as potential medulloblastoma therapeutic reagents. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2004. p. 409–409.
• Vaidyanathan G, Boskovitz A, Friedman HS, Affleck DJ, Zalutsky MR. Somatostatin targeted radiotherapeuiccs for medulloblastoma. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2004. p. 416–416.
• Vaidyanathan G, Welsh PC, Vitorello KC, Snyder S, Friedman HS, Zalutsky MR. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1362–70.
• Shankar S, Vaidyanathan G, Affleck DJ, Peixoto K, Bigner DD, Zalutsky MR. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nucl Med Biol. 2004 Oct;31(7):909–19.
• Boyd M, Tan KW, Ross SC, Dorrens J, Zalutsky MR, Mairs RJ. Investigation of cell kill in a targeted radiotherapy/gene therapy strategy utilising radiation induced biological bystander effects. In: JOURNAL OF GENE MEDICINE. JOHN WILEY & SONS LTD; 2004. p. S30–S30.
• Cosimo E, Boyd M, McCluskey A, Robson T, Zalutsky MR, Mairs RJ. Enhancement of targeted radiotherapy in neuroblastoma: a novel gene therapy approach. In: JOURNAL OF GENE MEDICINE. JOHN WILEY & SONS LTD; 2004. p. S27–S27.
• Boyd M, Mairs RJ, Ross S, Dorrens J, Zalutsky MR. A tumour specific targeted radiotherapy/gene therapy for the treatment of malignant disease. In: JOURNAL OF GENE MEDICINE. JOHN WILEY & SONS LTD; 2004. p. S33–4.
• Vaidyanathan G, Affleck DJ, Alston KL, Welsh P, Zalutsky MR. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. Nucl Med Commun. 2004 Sep;25(9):947–55.
• Boskovitz A, Wikstrand CJ, Kuan C-T, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther. 2004 Sep;4(9):1453–71.
• Akabani G, Rizzieri DA, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, et al. Phase I trial study of [131]I-labeled chimeric 81C6 mAb for the treatment of patients with non-Hodgkin's lymphoma. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER; 2004. p. S222–S222.
• Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 2004 Aug 1;104(3):642–8.
• Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med. 2004 Aug;6(8):937–47.
• Boyd M, Cosimo E, McCluskey AG, Clark AM, Robson T, McCarthy HO, et al. Enhancement of targeted radiotehrapy in neuroblastoma: A novel gene therapy approach. In: BRITISH JOURNAL OF CANCER. NATURE PUBLISHING GROUP; 2004. p. S19–S19.
• Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer. 2004 Apr 19;90(8):1469–73.
• Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl Med Biol. 2004 Apr;31(3):345–55.
• Vaidyanathan G, Shankar S, Affleck DJ, Alston K, Norman J, Welsh P, et al. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety. Bioorg Med Chem. 2004 Apr 1;12(7):1649–56.
• Vaidyanathan G, Affleck DJ, Norman J, Welsh P, Liu W, Johnson SP, et al. O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase. Bioconjug Chem. 2004;15(2):402–8.
• Zalutsky MR, Petelenz B. Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland. Nucl Med Rev Cent East Eur. 2004;7(2):195.
• Vaidyanathan G, Zalutsky MR. Imaging drug resistance with radiolabeled molecules. Curr Pharm Des. 2004;10(24):2965–79.
• Wilbur DS, Chyan M-K, Hamlin DK, Kegley BB, Risler R, Pathare PM, et al. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjug Chem. 2004;15(1):203–23.
• Boskovitz A, Akabani G, Zhao XG, Alston K, Zalutsky MR. Astatine-211 labeled Herceptin: An alpha-particle emitting radiotherapeutic. In: CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2003. p. 6189S-6189S.
• Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res. 2003 Nov 15;9(15):5514–20.
• Carlin S, Akabani G, Zalutsky MR. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med. 2003 Nov;44(11):1827–38.
• Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct;65(1):27–35.
• Zalutsky MR. Targeted radiotherapy of brain tumours. In: BRITISH JOURNAL OF CANCER. NATURE PUBLISHING GROUP; 2003. p. S6–S6.
• Vaidyanathan G, Friedman HS, Affleck DJ, Schottelius M, Wester H-J, Zalutsky MR. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res. 2003 May;9(5):1868–76.
• Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. Nucl Med Biol. 2003 May;30(4):351–9.
• Akabani G, Kennel SJ, Zalutsky MR. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. J Nucl Med. 2003 May;44(5):792–805.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. N-succinimidyl 3-[211AT]astato-4-guanidinomethylbenzoate: An acylation agent for labeling internalizing antibodies with alpha-particle emitting (211)AT. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC; 2003. p. U265–U265.
• Wilbur DS, Hamlin DK, Chyan MK, Foulon C, Zalutsky MR, Wedge T, et al. Optimizing methods for labeling biomolecules with astatine-211. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC; 2003. p. U264–5.
• Zalutsky MR, Pozzi O, Zhao XG, Alston KL. Evaluation of astatine-211 labeled targeted radiotherapeutics. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC; 2003. p. U264–U264.
• Shankar S, Vaidyanathan G, Affleck D, Welsh PC, Zalutsky MR. N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjug Chem. 2003;14(2):331–41.
• Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259–75.
• Carlin S, Mairs RJ, Welsh P, Zalutsky MR. Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells. Nucl Med Biol. 2002 Oct;29(7):729–39.
• Shankar S, Vaidyanathan G, Affleck DJ, Welsh P, LeGrand H, Zalutsky MR. Negatively charged substituent-bearing acylation agent for the radiohalogenation of mAbs. JOURNAL OF NUCLEAR MEDICINE. 2002 May 1;43(5):366P-366P.
• Akabani G, Rizzieri D, Coleman RE, Metzler SD, Zalutsky MR, Bigner DD. Radioimmunotherapy of refractory non-Hodgkin's lymphoma with I-131-labeled chimeric 81C6 anti-tenascin monoclonal antibody: Dosimetry study. JOURNAL OF NUCLEAR MEDICINE. 2002 May 1;43(5):313P-313P.
• Vaidyanathan G, Affleck DJ, Welsh P, Schottelius M, Wester H, Norman JA, et al. Synthesis and in vitro evaluation of glycated octreotate conjugates labeled with radioiodine and At-211 via a tin precursor. JOURNAL OF NUCLEAR MEDICINE. 2002 May 1;43(5):92P-92P.
• Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 1;20(5):1389–97.
• Reardon DA, Akabani G, Edward Coleman R, Friedman AH, Friedman HS, Herndon JE, et al. Phase II Trial of Murine ¹³¹I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas. Journal of Clinical Oncology. 2002 Mar 1;20(5):1389–97.
• Berry CR, DeGrado TR, Nutter F, Garg PK, Breitschwerdt EB, Spaulding K, et al. Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. Vet Radiol Ultrasound. 2002;43(2):183–6.
• Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol. 2002 Jan;29(1):1–11.
• Rizzieri DA, Akabani G, Coleman RE, Zalutsky MR, Niedzwiecki D, Payne N, et al. Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL). BLOOD. 2001 Nov 16;98(11):247B-247B.
• Zalutsky MR, Zhao XG, Alston KL, Bigner D. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J Nucl Med. 2001 Oct;42(10):1508–15.
• Foulon CF, Welsh PC, Bigner DD, Zalutsky MR. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nucl Med Biol. 2001 Oct;28(7):769–77.
• Mairs RJ, Carlin S, Boyd M, Cunningham SH, Welsh P, Zalutsky MR. Transfection of the sodium iodide symporter gene for tumour targeting with radioiodine and [At-211]radioastatine. BRITISH JOURNAL OF CANCER. 2001 Jul 1;85:24–24.
• Zalutsky MR, Akabani G, Friedman HS, Cokgor I, Coleman RE, Friedman AH, et al. Radioimmunotherapy of recurrent glioma patients using alpha-particle emitting astatine-211 labeled chimeric anti-tenascin monoclonal antibody. JOURNAL OF NUCLEAR MEDICINE. 2001 May 1;42(5):121P-122P.
• Cokgor I, Akabani G, Friedman HS, Friedman AH, Zalutsky MR, Zehngebot LM, et al. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. Cancer. 2001 May 1;91(9):1809–13.
• Meyer DE, Kong GA, Dewhirst MW, Zalutsky MR, Chilkoti A. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res. 2001 Feb 15;61(4):1548–54.
• Vaidyanathan G, Shankar S, Zalutsky MR. Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues. Bioconjug Chem. 2001;12(5):786–97.
• Vaidyanathan G, Shankar S, Affleck DJ, Welsh PC, Slade SK, Zalutsky MR. Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues. Bioconjug Chem. 2001;12(5):798–806.
• Vaidyanathan G, Affleck DJ, Li J, Welsh P, Zalutsky MR. A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). Bioconjug Chem. 2001;12(3):428–38.
• Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR, et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer. 2000 Dec 15;88(6):962–9.
• Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000 Nov 15;18(22):3862–72.
• Bardiès M, Pihet P. Dosimetry and microdosimetry of targeted radiotherapy. Curr Pharm Des. 2000 Sep;6(14):1469–502.
• Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 2000 Sep;6(14):1433–55.
• Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 2000 Aug 15;60(16):4453–60.
• Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS. Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry. Int J Radiat Biol. 2000 Aug;76(8):1129–41.
• Xu F, Leadon SA, Yu Y, Boyer CM, O’Briant K, Ward K, et al. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res. 2000 Aug;6(8):3334–41.
• Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Microdosimetry of alpha-particle-emitting At-211-labelled monoclonal antibody (MAb) using histological images of malignant brain tumors. JOURNAL OF NUCLEAR MEDICINE. 2000 May 1;41(5):84P-84P.
• Vaidyanathan G, Affleck D, Welsh P, Srinivasan A, Schmidt M, Zalutsky MR. Radioiodination and astatination of octreotide by conjugation labeling. Nucl Med Biol. 2000 May;27(4):329–37.
• Chilkoti A, Meyer DE, Kong GH, Dewhirst MW, Foulon C, Zalutsky MR. Genetically engineered biopolymer conjugate for thermal targeting of anticancer therapeutics. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2000 Mar 26;219:U453–U453.
• Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947–58.
• Meyer DE, Kong GA, Dewhirst MW, Foulon C, Zalutsky MR, Chilkoti A. Genetically engineered polypeptide carrier for thermal targeting of anticancer therapeutics. American Chemical Society, Polymer Preprints, Division of Polymer Chemistry. 2000 Mar 1;41(1):1020–1.
• Vaidyanathan G, Affleck D, Welsh P, Srinivasan A, Schmidt M, Zalutsky MR. Radioiodination and astatination of octreotide by conjugation labeling. Journal of Inorganic Biochemistry. 2000 Feb 29;78(3):329–37.
• Zalutsky MR. Radiohalogens for radioimmunotherapy. In: Radioimmunotherapy of Cancer. 2000. p. 81–106.
• Vaidyanathan G, Affleck DJ, Cavazos CM, Johnson SP, Shankar S, Friedman HS, et al. Radiolabeled guanine derivatives for the in vivo mapping of O(6)-alkylguanine-DNA alkyltransferase: 6-(4-[(18)F]Fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[(131)I]Iodo-benzyloxy)-9H-purin-2-ylamine. Bioconjug Chem. 2000;11(6):868–75.
• Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol. 1999 Oct;26(7):781–90.
• Zalutsky MR, Akabani G, Cokgor I, Friedman HS, Coleman RE, Friedman AH, et al. Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients. EUROPEAN JOURNAL OF NUCLEAR MEDICINE. 1999 Sep 1;26(9):1215–1215.
• McLendon RE, Archer GE, Larsen RH, Akabani G, Bigner DD, Zalutsky MR. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491–9.
• Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med. 1999 Jul;40(7):1197–203.
• Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, et al. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin Cancer Res. 1999 Jun;5(6):1539–49.
• Kuan CT, Reist CJ, Foulon CF, Lorimer IAJ, Archer G, Pegram CN, et al. I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. CLINICAL CANCER RESEARCH. 1999 Jun 1;5(6):1539–49.
• Murud KM, Larsen RH, Hoff P, Zalutsky MR. Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates. Nucl Med Biol. 1999 May;26(4):397–403.
• Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl Med Biol. 1999 May;26(4):405–11.
• Akabani G, Reist CJ, Cokgor I, Friedman AH, Friedman HS, Coleman RE, et al. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med. 1999 Apr;40(4):631–8.
• Vaidyanathan G, Zalutsky MR. Low molecular weight radiopharmaceuticals: Radiohalogenated MIBG and IUdR analogues. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 1999 Mar 21;217:U41–U41.
• Kuan CT, Reist CJ, Foulon CF, Lorimer IAJ, Archer G, Pegram CN, et al. ¹²⁵I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clinical Cancer Research. 1999;5(6):1539–49.
• Vaidyanathan G, Srinivasan A, Affleck DJ, Welsh PC, Slade SK, Schmidt MA, et al. Octreotide analogues labeled with radioiodine and astatine-211. Journal of Labelled Compounds and Radiopharmaceuticals. 1999 Jan 1;42(SUPPL. 1).
• Foulon CF, Bigner DD, Zalutsky MR. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Bioconjug Chem. 1999;10(5):867–76.
• Olafsen T, Bruland O, Zalutsky M, Sandlie I. Erratum: Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling (Nuclear Medicine and Biology (1995) 22 (765- 771)). Nuclear Medicine and Biology. 1999 Jan 1;26(5):599.
• Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodinated D-peptides as prosthetic groups for radiolabeling internalizing antibodies. Journal of Labelled Compounds and Radiopharmaceuticals. 1999 Jan 1;42(SUPPL. 1).
• Larsen RH, Murud KM, Akabani G, Hoff P, Bruland ØS, Zalutsky MR. ²¹¹At- and ¹³¹I-labeled bisphosphonates with high in vivo stability and bone accumulation. Journal of Nuclear Medicine. 1999;40(7):1197–203.
• Reist CJ, Bigner DD, Zalutsky MR. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495–502.
• Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res. 1998 Sep;150(3):263–8.
• Hauck ML, Zalutsky MR. The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. Clin Cancer Res. 1998 Sep;4(9):2071–7.
• Vaidyanathan G, Zalutsky MR. Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction. Nucl Med Biol. 1998 Jul;25(5):487–96.
• Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer. 1998 Jun;77(12):2061–8.
• Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998 Jun;16(6):2202–12.
• Berry CR, Vaidyanathan G, Fisher PE, Zalutsky MR, Coleman RE, DeGrado TR. Myocardial kinetics of meta-[I-131]iodobenzylguanidine in an adriamycin cardiomyopathy rat model. JOURNAL OF NUCLEAR MEDICINE. 1998 May 1;39(5):47P-47P.
• Reist CJ, Bigner DD, Zalutsky MR. Human IgG(2) constant region enhances the in vivo stability of monoclonal antibody 81C6 compared to its murine parent. JOURNAL OF NUCLEAR MEDICINE. 1998 May 1;39(5):77P-77P.
• Valdyanathan G, Friedman HS, Zalutsky MR. N.C.A. 5-Iodo-1(2-deoxy,2-fluoro-beta-D-arabinofuranosyl)uracil (FIAU): Tissue uptake in D-54 glioma xenograft mouse model and cytotoxicity to D-247 glioma cells in vitro. JOURNAL OF NUCLEAR MEDICINE. 1998 May 1;39(5):104P-105P.
• Foulon CF, Bigner DD, Zalutsky MR. Pretargeted radioimmunotherapy using anti-tenascin 81C6-streptavidin conjugates and radiolabeled biotin: Preparation of reagents. JOURNAL OF NUCLEAR MEDICINE. 1998 May 1;39(5):105P-106P.
• Larsen RH, Slade S, Zalutsky MR. Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. Nucl Med Biol. 1998 May;25(4):351–7.
• Vaidyanathan G, Zalutsky MR. Targeted therapy using astatinated radiopharmaceuticals. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 1998 Apr 2;215:U946–U946.
• Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol. 1998 Apr;4(2):148–58.
• Hauck ML, Larsen RH, Welsh PC, Zalutsky MR. Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia. Br J Cancer. 1998 Mar;77(5):753–9.
• Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res. 1998 Feb;149(2):155–62.
• Foulon CF, Alston KL, Zalutsky MR. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl Med Biol. 1998 Feb;25(2):81–8.
• Vaidyanathan G, Zalutsky MR, DeGrado TR. Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. Bioconjug Chem. 1998;9(6):758–64.
• DeGrado TR, Zalutsky MR, Coleman RE, Vaidyanathan G. Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart. Nucl Med Biol. 1998 Jan;25(1):59–64.
• Akabani G, Zalutsky MR. Microdosimetry of astatine-211 using histological images: application to bone marrow. Radiat Res. 1997 Dec;148(6):599–607.
• Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl Med Biol. 1997 Oct;24(7):639–47.
• Larsen RH, Vaidyanathan G, Zalutsky MR. Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. Int J Radiat Biol. 1997 Jul;72(1):79–90.
• Vaidyanathan G, Zalutsky MR. A New Route to Guanidines from Bromoalkanes. The Journal of Organic Chemistry. 1997 Jul 1;62(14):4867–9.
• Vaidyanathan G, Zhao X-G, Larsen RH, Zalutsky MR. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. British Journal of Cancer. 1997 Jul;76(2):226–33.
• Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol. 1997 Jul;24(5):451–9.
• Zalutsky MR. Growth factor receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997 Jun;41(2):71–7.
• Reist CJ, Foulon CF, Bigner DD, Zalutsky MR. A method for labeling internalizing antibodies with astatine-211. JOURNAL OF NUCLEAR MEDICINE. 1997 May 1;38(5):15–15.
• DeGrado TR, Zalutsky MR, Vaidyanathan G. Mechanisms of uptake in isolated rat heart of potential radiotherapeutic agent [At-211]meta-astatobenzylguanidine (MABG). JOURNAL OF NUCLEAR MEDICINE. 1997 May 1;38(5):106–106.
• Akabani G, Zalutsky MR. Microdosimetry and small-scale dosimetry of At-211 in bone marrow: An analysis based on histological imaging. JOURNAL OF NUCLEAR MEDICINE. 1997 May 1;38(5):963–963.
• Kassis AI, Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ. Survival and DNA damage in V79 cells exposed to the alpha emitters 5-[At-211]astato-2'-deoxy-uridine and [At-211]astatide. JOURNAL OF NUCLEAR MEDICINE. 1997 May 1;38(5):964–964.
• Akabani G, Thorstad WL, Brown MT, Coleman RE, Zalutsky MR, Bigner DD. Dosimetry methods for patients with malignant CNS tumors treated with I-131 81C6 via surgically created cystic resection cavity. JOURNAL OF NUCLEAR MEDICINE. 1997 May 1;38(5):395–395.
• Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 1997 Apr 15;57(8):1510–5.
• Zalutsky MR, Stabin MG, Larsen RH, Bigner DD. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nucl Med Biol. 1997 Apr;24(3):255–61.
• Vaidyanathan G, Zalutsky MR. Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol. 1997 Feb;24(2):171–8.
• Vaidyanathan G, Zhao XG, Strickland DK, Zalutsky MR. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med. 1997 Feb;38(2):330–4.
• Foulon CF, Schoultz BW, Zalutsky MR. Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide. Nucl Med Biol. 1997 Feb;24(2):135–43.
• Vaidyanathan G, Zhao XG, Larsen RH, Zalutsky MR. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. Br J Cancer. 1997;76(2):226–33.
• Hauck ML, Coffin DO, Dodge RK, Dewhirst MW, Mitchell JB, Zalutsky MR. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia. 1997;13(3):307–16.
• Hauck ML, Dewhirst MW, Bigner DD, Zalutsky MR. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin Cancer Res. 1997 Jan;3(1):63–70.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate. Bioconjug Chem. 1997;8(5):724–9.
• Vaidyanathan G, Zhao XG, Larsen RH, Zalutsky MR. 3-[²¹¹At]astato-4-fluorobenzylguanidine: A potential therapeutic agent with prolonged retention by neuroblastoma cells. British Journal of Cancer. 1997;76(2):226–33.
• Foulon CF, Alston KL, Zalutsky MR. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. Bioconjug Chem. 1997;8(2):179–86.
• Berry CR, Garg PK, Zalutsky MR, Coleman RE, DeGrado TR. Uptake and retention kinetics of para-fluorine-18-fluorobenzylguanidine in isolated rat heart. J Nucl Med. 1996 Dec;37(12):2011–6.
• Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 1996 Nov 1;56(21):4970–7.
• Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. A method for the radiohalogenation of internalizing antibodies. JOURNAL OF NUCLEAR MEDICINE. 1996 Oct 1;37(10):1825–1825.
• Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol. 1996 Oct;41(10):1915–31.
• Vaidyanathan G, Friedman HS, Keir ST, Zalutsky MR. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl Med Biol. 1996 Aug;23(6):851–6.
• Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996 Jun;2(6):963–72.
• DeGrado TR, Zalutsky MR, Coleman RE, Vaidyanathan G. Effects of specific activity on uptake and retention of metaiodobenzylguanidine (MIBG) in the heart: Revisited. JOURNAL OF NUCLEAR MEDICINE. 1996 May 1;37(5):701–701.
• Vaidyanathan G, Affleck DJ, Welsh PC, Slade SA, Alston KL, Zalutsky MR. Fluorine-18 labeling of [Nle(4),D-Phe(7)]-alpha-MSH, an alpha-melanocyte stimulating hormone (alpha-MSH) analogue. JOURNAL OF NUCLEAR MEDICINE. 1996 May 1;37(5):875–875.
• Vaidyanathan G, Friedman HS, Keir ST, Zalutsky MR. Meta-[At-211]astatobenzylguanidine (MABG): In vivo evaluation in an athymic mouse human neuroblastoma xenograft model. JOURNAL OF NUCLEAR MEDICINE. 1996 May 1;37(5):236–236.
• Garg PK, Berry CR, DeGrado RT, Nutter F, Breitschwerdt E, Zalutsky MR, et al. PET imaging of pheochromocytoma (PHEO) in dogs using PARA [F-18]fluorobenzylguanidine (PFBG). JOURNAL OF NUCLEAR MEDICINE. 1996 May 1;37(5):915–915.
• Foulon CF, Larsen RH, Zalutsky MR. Preparation and binding properties of an astatine-211 labeled biotin conjugate. JOURNAL OF NUCLEAR MEDICINE. 1996 May 1;37(5):900–900.
• Zalutsky MR, Archer GE, Garg PK, Batra SK, Bigner DD. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl Med Biol. 1996 May;23(4):449–58.
• Hauck ML, Dewhirst MW, Zalutsky MR. The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. Nucl Med Biol. 1996 May;23(4):551–7.
• Vaidyanathan G, Friedman HS, Keir ST, Zalutsky MR. Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. Br J Cancer. 1996 May;73(10):1171–7.
• McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):69–80.
• Vaidyanathan G, Larsen RH, Zalutsky MR. 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 1996 Mar 15;56(6):1204–9.
• Vaidyanathan G, Larsen RH, Zalutsky MR. Particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Research. 1996 Mar 15;56(6):1204–9.
• Larsen RH, Wieland BW, Zalutsky MR. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction. Appl Radiat Isot. 1996 Feb;47(2):135–43.
• Vaidyanathan G, Affleck DJ, Slade SA, Zalutsky MR. Labeling of Monoclonal Antibodies (MAbs) with N-Succinimidyl 3-hydroxy-4-[131I]iodobenzoate (mSHIB). Journal of Labelled Compounds and Radiopharmaceuticals. 1996;536.
• Garg PK, Alston KL, Zalutsky MR. Catabolism of Label from an F(ab')2 Fragment Radioiodinated Using N-Succinimidyl 3-iodobenzoate and Iodogen Methods. Journal of Labelled Compounds and Radiopharmaceuticals. 1996;539.
• Olafsen T, Bruland OS, Zalutsky MR, Sandlie I. Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. Acta Oncol. 1996;35(3):297–301.
• Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol. 1996;35(3):373–9.
• Zalutsky MR, Schuster JM, Garg PK, Archer GE, Dewhirst MW, Bigner DD. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Recent Results Cancer Res. 1996;141:101–22.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine. Bioconjug Chem. 1996;7(1):102–7.
• Vaidyanathan G, Larsen RH, Zalutsky MR. 5-[At-211]astato-2'-deoxyuridine, an alpha-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. CANCER RESEARCH. 1996;56(6):1204–9.
• Berry CR, Garg PK, DeGrado TR, Hellyer P, Weber W, Garg S, et al. Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model. J Nucl Cardiol. 1996;3(2):119–29.
• Larsen RH, Wieland BW, Zalutsky MR. Evaluation of an internal cyclotron target for the production of ²¹¹at via the ²⁰⁹Bi (α,2n)²¹¹at reaction. Applied Radiation and Isotopes. 1996;47(2):135–43.
• Garg PK, Alston KL, Welsh PC, Zalutsky MR. Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem. 1996;7(2):233–9.
• Garg PK, Alston KL, Welsh PC, Zalutsky MR. Preliminary Evaluation of Radioiodinated Alpha-melanocyte Stimulating Hormone (a-MSH) and its Analogue Using N-succinimidyl 3-iodobenzoate and Iodogen Methods. Journal of Labelled Compounds and Radiopharmaceuticals. 1996;496.
• Smellie WJ, Dean CJ, Sacks NP, Zalutsky MR, Garg PK, Carnochan P, et al. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods. Cancer Res. 1995 Dec 1;55(23 Suppl):5842s-5846s.
• SMELLIE WJB, DEAN CJ, SACKS NPM, ZALUTSKY MR, GARG PK, CARNOCHAN P, et al. RADIOIMMUNOTHERAPY OF BREAST-CANCER XENOGRAFTS WITH MONOCLONAL-ANTIBODY ICR12 AGAINST C-ERBB2 P185 - COMPARISON OF IODOGEN AND N-SUCCINIMIDYL 4-METHYL-3-(TRI-N-BUTYLSTANNYL)BENZOATE RADIOIODINATION METHODS. In: CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 1995. p. S5842–6.
• Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. 1995 Oct 1;55(19):4375–82.
• Olafsen T, Bruland OS, Zalutsky MR, Sandlie I. Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. Nucl Med Biol. 1995 Aug;22(6):765–71.
• Vaidyanathan G, Zalutsky MR. Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection. Nucl Med Biol. 1995 Aug;22(6):759–64.
• Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995 Jul 15;55(14):3140–8.
• Mairs RJ, Zalutsky MR. New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. Br J Cancer. 1995 Jul;72(1):250.
• Garg PK, John CS, Zalutsky MR. Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. Nucl Med Biol. 1995 May;22(4):467–73.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995 Apr;36(4):644–50.
• Schuster JM, Zalutsky MR, Noska MA, Dodge R, Friedman HS, Bigner DD, et al. Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. Int J Hyperthermia. 1995;11(1):59–72.
• Johnson EL, Turkington TG, Jaszczak RJ, Gilland DR, Vaidyanathan G, Greer KL, et al. Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol. 1995 Jan;22(1):45–54.
• Mairs RJ, Russell J, Cunningham S, O’Donoghue JA, Gaze MN, Owens J, et al. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer. 1995;31A(4):576–81.
• Strickland DK, Vaidyanathan G, Friedman HS, Zalutsky MR. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. J Neurooncol. 1995;25(1):9–17.
• Garg PK, Alston KL, Zalutsky MR. Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. Bioconjug Chem. 1995;6(4):493–501.
• Vaidyanathan G, Zalutsky MR. No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. Nucl Med Biol. 1995 Jan;22(1):61–4.
• Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. J Neurooncol. 1995;24(1):109–22.
• Degrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995 Jan;22(1):1–12.
• Strickland DK, Vaidyanathan G, Zalutsky MR. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 1994 Oct 15;54(20):5414–9.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. J Med Chem. 1994 Oct 14;37(21):3655–62.
• Page RL, Garg PK, Vaidyanathan G, Zalutsky MR. Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs. Nucl Med Biol. 1994 Oct;21(7):911–9.
• Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994 Sep 1;54(17):4719–25.
• Page RL, Garg PK, Garg S, Archer GE, Bruland OS, Zalutsky MR. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. J Nucl Med. 1994 Sep;35(9):1506–13.
• He X, Archer GE, Wikstrand CJ, Morrison SL, Zalutsky MR, Bigner DD, et al. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol. 1994 Jul;52(2):127–37.
• Vaidyanathan G, Strickland DK, Zalutsky MR. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent. Int J Cancer. 1994 Jun 15;57(6):908–13.
• BERRY CR, GARG PK, DEGRADO TR, GARG S, HELLYER P, WEBER WJ, et al. PARA[F-18] FLUOROBENZYLGUANIDINE (PFBG) KINETICS IN A CANINE CORONARY-ARTERY OCCLUSION MODEL. JOURNAL OF NUCLEAR MEDICINE. 1994 May 1;35(5):P157–P157.
• JOHNSON EL, TURKINGTON TG, JASZCZAK RJ, ZALUTSKY MR, GILLAND DR, VAIDYANATHAN G, et al. QUANTITATIVE IMAGING OF AT-211 RADIOTHERAPEUTIC AGENTS IN SMALL VOLUMES. JOURNAL OF NUCLEAR MEDICINE. 1994 May 1;35(5):P180–P180.
• DEGRADO TR, ZALUTSKY MR, AFFLECK DJ, VAIDYANATHAN G. MECHANISTIC STUDIES OF METAIODOBENZYLGUANIDINE (METAIODOBENZYLGUANIDINE) UPTAKE AND RETENTION IN ISOLATED RAT-HEART. JOURNAL OF NUCLEAR MEDICINE. 1994 May 1;35(5):P57–P57.
• GARG PK, BERRY CR, DEGRADO TR, GARG S, HELLYER P, COLEMAN RE, et al. MYOCARDIAL AND ADRENAL UPTAKE OF PARA [F-18] FLUOROBENZYLGUANIDINE (PFBG) IN THE DOG. JOURNAL OF NUCLEAR MEDICINE. 1994 May 1;35(5):P255–P255.
• JANG S, TURKINGTON T, JASZCZAK RJ, LI J, GREER KL, ZALUTSKY MR, et al. QUANTITATIVE MEASUREMENTS FOR SMALL ORGANS OF MONKEY. JOURNAL OF NUCLEAR MEDICINE. 1994 May 1;35(5):P179–P179.
• VAIDYANATHAN G, AFFLECK DJ, SLADE SA, WELSH PC, ZALUTSKY MR. SYNTHESIS AND PRELIMINARY EVALUATION OF 4-[F-18]FLUORO-3-IODOBENZYLGUANIDINE (FIBG) - A METAIODOBENZYLGUANIDINE ANALOG FOR PET. JOURNAL OF NUCLEAR MEDICINE. 1994 May 1;35(5):P248–P248.
• Batra SK, Niswonger ML, Wikstrand CJ, Pegram CN, Zalutsky MR, Morrison SL, et al. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Hybridoma. 1994 Apr;13(2):87–97.
• Mairs RJ, Gaze MN, Watson DG, Skellern GG, Constable P, McKellar K, et al. Carrier-free 131I-meta-iodobenzylguanidine: comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine. Nucl Med Commun. 1994 Apr;15(4):268–74.
• Jaszczak RJ, Li J, Wang H, Zalutsky MR, Coleman RE. Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT. Phys Med Biol. 1994 Mar;39(3):425–37.
• Garg PK, Garg S, Zhao XG, Welsh PC, Zalutsky MR. Catabolism of label from Mel-14 F(ab')2 fragment radiohalogenated using N-succinimidyl 3-halobenzoates. Journal of Labelled Compounds and Radiopharmaceuticals. 1994 Jan 1;35:310–2.
• Garg PK, Garg S, Zalutsky MR. Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine. Nucl Med Biol. 1994 Jan;21(1):97–103.
• Vaidyanathan G, Strickland DK, Affleck DA, Welsh P, Zalutsky MR. Meta-[²¹¹At]astatobenzylguanidine: Further validation of in vitro and in vivo uptake mechanisms. Journal of Labelled Compounds and Radiopharmaceuticals. 1994;35:589–91.
• Gaze MN, Mairs RJ, Vaidyanathan G, Zalutsky MR. Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma. Prog Clin Biol Res. 1994;385:347–53.
• Vaidyanathan G, Affleck DA, Welsh P, Zalutsky MR. Fluorine-18 labeled chemotactic peptide: A potential agent for the PET imaging of focal infection. Journal of Labelled Compounds and Radiopharmaceuticals. 1994 Jan 1;35:365–7.
• Vaidyanathan G, Affleck D, Zalutsky MR. Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments. Nucl Med Biol. 1994 Jan;21(1):105–10.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. (4-[¹⁸F]fluoro-3-iodobenzyl)guanidine, a potential mibg analogue for positron emission tomography. Journal of Medicinal Chemistry. 1994;37(21):3655–62.
• ZALUTSKY MR. RADIONUCLIDE THERAPY - A REVIEW. In: Amaldi U, Larsson B, editors. HADRONTHERAPY IN ONCOLOGY. ELSEVIER SCIENCE PUBL B V; 1994. p. 664–76.
• Vaidyanathan G, Zalutsky MR. Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. Bioconjug Chem. 1994;5(4):352–6.
• Vaidyanathan G, Strickland DK, Affleck DA, Welsh P, Zalutsky MR. Meta-[²¹¹At]astatobenzylguanidine: Further validation of in vitro and in vivo uptake mechanisms. In: Journal of Labelled Compounds and Radiopharmaceuticals. 1994. p. 589–91.
• VAIDYANATHAN G, AFFLECK DJ, SLADE SA, WELSH P, ZALUTSKY MR. NO-CARRIER-ADDED 4-FLUORO-3-IODOBENZYLGUANIDINE LABELED WITH I-131 ([I-131]FIBG) AND F-18 ([F-18]FIBG - POTENTIAL MIBG ANALOGS FOR PET IMAGING AND THERAPY OF NEUROENDOCRINE TUMORS. In: Rao RS, Deo MG, Sanghvi LD, Mittra I, editors. PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4. MONDUZZI EDITORE; 1994. p. 3013–7.
• GARG PK, BERRY CR, GARG S, DEGRADO TR, ZALUTSKY MR, COLEMAN RE. PARA-[F-18]FLUOROBENZYLGUANIDINE ([F-18]PFBG) - FURTHER EVALUATION OF A POTENTIAL PET RADIOTRACER IN DOGS. In: Rao RS, Deo MG, Sanghvi LD, Mittra I, editors. PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4. MONDUZZI EDITORE; 1994. p. 113–8.
• DEGRADO TR, ZALUTSKY MR, AFFLECK DJ, VAIDYANATHAN G. UPTAKE MECHANISMS OF I-123 METAIODOBENZYLGUANIDINE (METAIODOBENZYLGUANIDINE) IN ISOLATED RAT-HEART. CIRCULATION. 1993 Oct 1;88(4):355–355.
• Garg S, Garg PK, Zhao XG, Friedman HS, Bigner DD, Zalutsky MR. Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Nucl Med Biol. 1993 Oct;20(7):835–42.
• Turkington TG, Zalutsky MR, Jaszczak RJ, Garg PK, Vaidyanathan G, Coleman RE. Measuring astatine-211 distributions with SPECT. Phys Med Biol. 1993 Aug;38(8):1121–30.
• Schold SC, Zalutsky MR, Coleman RE, Glantz MJ, Friedman AH, Jaszczak RJ, et al. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol. 1993 Jun;28(6):488–96.
• VAIDYANATHAN G, HARRISON C, WELSH P, AFFLECK D, ZALUTSKY MR. INVITRO CYTOTOXICITY OF M-[AT-211]ASTATOBENZYLGUANIDINE (MABG). JOURNAL OF NUCLEAR MEDICINE. 1993 May 1;34(5):P218–P218.
• GARG S, GARG PK, ZALUTSKY MR. LABELING MONOCLONAL-ANTIBODIES (MABS) WITH AT-211 USING N-SUCCINIMIDYL 5-[AT-211]ASTATO-3-PYRIDINECARBOXYLATE (SAPC). JOURNAL OF NUCLEAR MEDICINE. 1993 May 1;34(5):P99–100.
• PAGE RL, GARG PK, GARG S, BRULAND OS, ZALUTSKY MR. IMAGING OSTEOSARCOMA IN DOGS USING F-18 LABELED TP-3 MONOCLONAL-ANTIBODY (MAB) FRAGMENT AND PET. JOURNAL OF NUCLEAR MEDICINE. 1993 May 1;34(5):P216–P216.
• GARG PK, GARG S, COLEMAN RE, ZALUTSKY MR. PARA[F-18]FLUOROBENZYLGUANIDINE (PFBG) - A POTENTIAL TRACER FOR IMAGING HEART AND TUMOR USING PET. JOURNAL OF NUCLEAR MEDICINE. 1993 May 1;34(5):P79–P79.
• TURKINGTON TG, ZALUTSKY MR, JASZCZAK RJ, GARG P, VAIDYANATHAN G, COLEMAN RE. MEASURING ASTATINE-211 DISTRIBUTIONS WITH SPECT. JOURNAL OF NUCLEAR MEDICINE. 1993 May 1;34(5):P191–P191.
• JASZCZAK RJ, LI J, WANG H, ZALUTSKY MR, COLEMAN RE. PINHOLE COLLIMATION FOR ULTRA-HIGH-RESOLUTION, SMALL-FIELD-OF-VIEW SPECT STUDIES. JOURNAL OF NUCLEAR MEDICINE. 1993 May 1;34(5):P10–P10.
• Garg PK, Garg S, Zalutsky MR. N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. Nucl Med Biol. 1993 May;20(4):379–87.
• BATRA SK, NISWONGER M, WIKSTRAND CJ, ZALUTSKY MR, MORRISON SL, BIGNER DD. GENERATION AND CHARACTERIZATION OF MOUSE-HUMAN CHIMERIC MEL-14 ANTIBODY. JOURNAL OF IMMUNOLOGY. 1993 Apr 15;150(8):A150–A150.
• Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot. 1993 Mar;44(3):621–8.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. Bioconjug Chem. 1993;4(1):78–84.
• Garg PK, Garg S, Bigner DD, Zalutsky MR. Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. Cancer Res. 1992 Sep 15;52(18):5054–60.
• Moseley RP, Papanastassiou V, Zalutsky MR, Ashpole RD, Evans S, Bigner DD, et al. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer. 1992 Aug 19;52(1):38–43.
• Vaidyanathan G, Bigner DD, Zalutsky MR. Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. J Nucl Med. 1992 Aug;33(8):1535–41.
• Zalutsky MR, Garg PK, Johnson SH, Utsunomiya H, Coleman RE. Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a canine myocardial infarct model. J Nucl Med. 1992 Apr;33(4):575–80.
• Vaidyanathan G, Zalutsky MR. Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. Int J Rad Appl Instrum B. 1992 Apr;19(3):275–81.
• Garg PK, Garg S, Degraff WG, Zalutsky MR, Mitchell JB. 4-Fluorobenzylamine and phenylalanine methyl ester conjugates of 2-nitroimidazole: evaluation as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys. 1992;22(3):593–6.
• Vaidyanathan G, Zalutsky MR. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem. 1992;3(6):499–503.
• Vaidyanathan G, Zalutsky MR. 1-(m-[²¹¹At]astatobenzyl)guanidine: Synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjugate Chemistry. 1992;3(6):499–503.
• Schuster JM, Garg PK, Bigner DD, Zalutsky MR. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res. 1991 Aug 15;51(16):4164–9.
• Garg S, Garg PK, Bigner DD, Zalutsky MR. Radioiodination and astatination of monoclonal antibodies using heterocyclic acylation agents. Journal of Labelled Compounds and Radiopharmaceuticals. 1991 Apr 5;30.
• Vaidyanathan G, Affleck DJ, Zalutsky MR. Aromatic acylation reagents for use in the radioiodination of proteins. Journal of Labelled Compounds and Radiopharmaceuticals. 1991 Apr 5;30.
• Garg PK, Garg S, Zalutsky MR. Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. Bioconjug Chem. 1991;2(1):44–9.
• Garg S, Garg PK, Zalutsky MR. N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. Bioconjug Chem. 1991;2(1):50–6.
• Worlock AJ, Zalutsky MR, Metzgar RS. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res. 1990 Nov 15;50(22):7246–51.
• Moseley RP, Davies AG, Richardson RB, Zalutsky M, Carrell S, Fabre J, et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer. 1990 Oct;62(4):637–42.
• Zalutsky MR, Moseley RP, Benjamin JC, Colapinto EV, Fuller GN, Coakham HP, et al. Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res. 1990 Jul 1;50(13):4105–10.
• Garg PK, Harrison CL, Zalutsky MR. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment. Cancer Res. 1990 Jun 15;50(12):3514–20.
• Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4207–11.
• GARG PK, VAIDYANATHAN G, GARG S, ZALUTSKY MR. RADIOIODINATION AND ASTATINATION OF MONOCLONAL-ANTIBODIES. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 1990 Apr 22;199:16-NUCL.
• National Cancer Institute Workshop statement. Advances in clinical imaging using positron emission tomography, September 14-16, 1988. The Workshop Panel. Arch Intern Med. 1990 Apr;150(4):735–9.
• Cope DA, Dewhirst MW, Friedman HS, Bigner DD, Zalutsky MR. Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res. 1990 Mar 15;50(6):1803–9.
• Colapinto EV, Zalutsky MR, Archer GE, Noska MA, Friedman HS, Carrel S, et al. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. Cancer Res. 1990 Mar 15;50(6):1822–7.
• Venkatesan PP, Shortkroff S, Zalutsky MR, Sledge CB. Rhenium heptasulfide: a potential carrier system for radiation synovectomy. Int J Rad Appl Instrum B. 1990;17(4):357–62.
• Zalutsky MR, Garg PK, Narula AS. Labeling monoclonal antibodies with halogen nuclides. Acta Radiol Suppl. 1990;374:141–5.
• Vaidyanathan G, Zalutsky MR. Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. Bioconjug Chem. 1990;1(6):387–93.
• Vaidyanathan G, Zalutsky MR. Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents. Bioconjug Chem. 1990;1(4):269–73.
• Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. Cancer Res. 1989 Oct 15;49(20):5543–9.
• Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7149–53.
• Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989 May 15;49(10):2807–13.
• ZALUTSKY MR, GARG PK. RADIOHALOGENATION OF ANTIBODIES. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 1989 Apr 9;197:84-NUCL.
• Garg PK, Archer GE, Bigner DD, Zalutsky MR. Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. Int J Rad Appl Instrum A. 1989;40(6):485–90.
• Garg PK, Slade SK, Harrison CL, Zalutsky MR. Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability. Int J Rad Appl Instrum B. 1989;16(7):669–73.
• Zalutsky MR, Bast RC, Knapp RC. Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. Int J Rad Appl Instrum B. 1989;16(4):405–11.
• Zalutsky MR, Bast RC, Knapp RC. Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. Nuclear Medicine and Biology. 1989 Jan 1;16(4):405–11.
• Narula AS, Zalutsky MR. No-Carrier-Added Astatination of N-Succinimidyl-3-(Tri-n-Butylstannyl) Benzoate (ATE) Via Electrophilic Destannylation¹. Radiochimica Acta. 1989 Jan 1;47(2–3):131–6.
• Colapinto EV, Humphrey PA, Zalutsky MR, Groothuis DR, Friedman HS, de Tribolet N, et al. Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. Cancer Res. 1988 Oct 15;48(20):5701–7.
• GARG PK, FRIEDMAN H, SLADE S, BIGNER DD, ZALUTSKY MR. ASTATINE-211 LABELED MONOCLONAL-ANTIBODY - A POTENTIAL AGENT FOR RADIOIMMUNOTHERAPY. EUROPEAN JOURNAL OF NUCLEAR MEDICINE. 1988 Aug 1;14(5–6):245–245.
• Lee Y, Bullard DE, Humphrey PA, Colapinto EV, Friedman HS, Zalutsky MR, et al. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res. 1988 May 15;48(10):2904–10.
• Zalutsky MR, Narula AS. Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. Cancer Res. 1988 Mar 15;48(6):1446–50.
• Lee YS, Bullard DE, Zalutsky MR, Coleman RE, Wikstrand CJ, Friedman HS, et al. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res. 1988 Feb 1;48(3):559–66.
• Zalutsky MR, Knapp RC, Bast RC. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. Int J Rad Appl Instrum B. 1988;15(4):431–7.
• Hayes DF, Noska MA, Kufe DW, Zalutsky MR. Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. Int J Rad Appl Instrum B. 1988;15(3):235–41.
• Zalutsky MR, Noska MA, Gallagher PW, Shortkroff S, Sledge CB. Use of liposomes as carriers for radiation synovectomy. Int J Rad Appl Instrum B. 1988;15(2):151–6.
• Narula AS, Zalutsky MR. Synthesis of N-succinimidyl-2,4-dimethoxy-3-(tri-N-butylstannyl) benzoate via regio-specifically generated lithium 2,4-dimethoxy-3-lithiobenzoate. Tetrahedron Letters. 1988 Jan 1;29(35):4385–8.
• Colapinto EV, Lee YS, Humphrey PA, Zalutsky MR, Friedman HS, Bullard DE, et al. The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. Br J Neurosurg. 1988;2(2):179–91.
• Zalutsky MR, Noska MA, Gallagher PW, Shortkroff S, Sledge CB. Use of liposomes as carriers for radiation synovectomy. Nuclear Medicine and Biology. 1988 Jan 1;15(2):151–6.
• Zalutsky MR, Knapp RC, Bast RC. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. Nuclear Medicine and Biology. 1988 Jan 1;15(4):431–7.
• Lee YS, Bullard DE, Zalutsky MR, Coleman RE, Wikstrand CJ, Friedman HS, et al. Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix 131I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model. Cancer Research. 1988 Jan 1;48(3):584–8.
• Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int J Rad Appl Instrum A. 1988;39(3):227–32.
• Sledge CB, Zuckerman JD, Shortkroff S, Zalutsky MR, Venkatesan P, Snyder MA, et al. Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-ferric hydroxide macroaggregates. J Bone Joint Surg Am. 1987 Sep;69(7):970–5.
• Zalutsky MR, de Sousa M, Venkatesan P, Shortkroff S, Zuckerman J, Sledge C. Evaluation of indium-111 chloride as a radiopharmaceutical for joint imaging in a rabbit model of arthritis. Invest Radiol. 1987 Sep;22(9):733–40.
• Wikstrand CJ, McLendon RE, Carrel S, Kemshead JT, Mach JP, Coakham HB, et al. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. J Neuroimmunol. 1987 May;15(1):37–56.
• Lee YS, Bullard DE, Wikstrand CJ, Zalutsky MR, Muhlbaier LH, Bigner DD. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res. 1987 Apr 1;47(7):1941–6.
• Zalutsky MR, Noska MA, Seltzer SE. Characterization of liposomes containing iodine-125-labeled radiographic contrast agents. Invest Radiol. 1987 Feb;22(2):141–7.
• Letvin NL, Zalutsky MR, Lambert JM, Chalifoux LV, Nadler LM, Schlossman SF, et al. Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys. Int J Rad Appl Instrum B. 1987;14(2):99–105.
• Zalutsky MR, Narula AS. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Int J Rad Appl Instrum A. 1987;38(12):1051–5.
• Bullard DE, Wikstrand CJ, Humphrey PA, Lee YS, Coleman RE, Zalutsky M, et al. Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs). Nuklearmedizin. 1986 Dec;25(6):210–5.
• Zalutsky MR, Noska MA, Gallagher PW. Properties of multilamellar liposomes containing^99mTcO4^-: Effect of distearoylphosphatidylcholine to sphingomyelin ratio. Nuclear Medicine and Biology. 1986 Dec 1;13(3):269–76.
• Hayes DF, Zalutsky MR, Kaplan W, Noska M, Thor A, Colcher D, et al. Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. Cancer Res. 1986 Jun;46(6):3157–63.
• Sledge CB, Zuckerman JD, Zalutsky MR, Atcher RW, Shortkroff S, Lionberger DR, et al. Treatment of rheumatoid synovitis of the knee with intraarticular injection of dysprosium 165-ferric hydroxide macroaggregates. Arthritis Rheum. 1986 Feb;29(2):153–9.
• Zalutsky MR. Radiohalogenation of monoclonal antibodies. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 1986 Jan;13(6):652–3.
• Zalutsky MR, Noska MA, Gallagher PW. Properties of multilamellar liposomes containing 99mTcO4-: effect of distearoylphosphatidylcholine to sphingomyelin ratio. Int J Rad Appl Instrum B. 1986;13(3):269–76.
• Zalutsky MR, Venkatesan PP, English RJ, Shortkroff S, Sledge CB, Adelstein SJ. Radiation synovectomy with 165Dy-FHMA: lymph node uptake and radiation dosimetry calculations. Int J Nucl Med Biol. 1986;12(6):457–65.
• Zalutsky MR, Hayes DF, Kufe DW. Radioiodination of DF3 antibody: Optimization using in vitro binding assays. Journal of Labelled Compounds and Radiopharmaceuticals. 1986 Jan 1;23(10–12):1301–3.
• Zalutsky M, Magistretti P, Gallagher P, Ghidoni R. Radioiodinated ganglioside GM1: a potential tool for the investigation of ganglioside function in vivo. Pharmacol Res Commun. 1985 Oct;17(10):897–912.
• Kilbourn MR, Zalutsky MR. Research and clinical potential of receptor based radiopharmaceuticals. J Nucl Med. 1985 Jun;26(6):655–62.
• Zalutsky MR, Colcher D, Kaplan WD, Kufe DW. Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. Int J Nucl Med Biol. 1985;12(3):227–33.
• De Sousa M, Carroll AM, Herman PG, Kerr S, Boulton J, Zalutsky MR. Distribution and mechanism of uptake of 111InCl3 in a tumor model for lymph node metastases. Int J Nucl Med Biol. 1985;12(2):89–96.
• Carroll AM, Zalutsky M, Schatten S, Bhan A, Perry LL, Sobotka C, et al. Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. Clin Immunol Immunopathol. 1984 Nov;33(2):268–81.
• Masuho Y, Zalutsky M, Knapp RC, Bast RC. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res. 1984 Jul;44(7):2813–9.
• Bloomer WD, McLaughlin WH, Lambrecht RM, Atcher RW, Mirzadeh S, Madara JL, et al. 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. Int J Radiat Oncol Biol Phys. 1984 Mar;10(3):341–8.
• Carroll AM, Zalutsky MR. Receptor-mediated radiopharmaceuticals. Trends in Pharmacological Sciences. 1984 Jan 1;5(C):57–60.
• Carroll AM, Zalutsky MR, Benacerraf B, Greene MI. Monoclonal antibodies to tissue-associated antigens as antitumor reagents. Surv Synth Pathol Res. 1984;3(3):189–200.
• Bloomer WD, McLaughlin WH, Lambrecht RM, Atcher RW, Mirzadeh S, Madara JL, et al. ²¹¹At radiocolloid therapy: Further observations and comparison with radiocolloids of ³²P, ¹⁶⁵Dy, and ⁹⁰Y. International Journal of Radiation Oncology, Biology, Physics. 1984;10(3):341–8.
• Colcher D, Zalutsky M, Kaplan W, Kufe D, Austin F, Schlom J. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res. 1983 Feb;43(2):736–42.
• Zalutsky MR, Wu J, Harper PV, Wickland T. Synthesis of ¹¹C-dl-tryptophan and its purification using high-pressure liquid chromatography. The International Journal Of Applied Radiation And Isotopes. 1981 Jan 1;32(3):182–4.
• Kirchner PT, Ryan J, Zalutsky M, Harper PV. Positron emission tomography for the evaluation of pancreatic disease. Semin Nucl Med. 1980 Oct;10(4):374–91.
• Friedman AM, Cheronis J, Zalutsky M. Preparation of ⁷⁷Br and ⁷⁶Br L-DOPA and 5-hydroxytryptophan analogues. Journal of Labelled Compounds and Radiopharmaceuticals. 1979 Jan 1;16(1):66–7.
• FRIEDMAN AM, CHERONIS J, ZALUTSKY M, COOPER M, HOFFMAN P, HELLER A, et al. PREPARATION OF BR-77 AND BR-76 L-DOPA AND 5-HYDROXYTRYPTOPHAN ANALOGS. In: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 1979. p. 66–7.
• Zalutsky M, Wickland T, Nickles J, Harper PV. Nitrogen-13 nitrous oxide for cerebral imaging studies. Journal of Nuclear Medicine. 1978 Jan 1;19(6):700.
• ZALUTSKY M, WICKLAND T, NICKLES J, HARPER PV. N-13 NITROUS-OXIDE FOR CEREBRAL IMAGING STUDIES. In: JOURNAL OF NUCLEAR MEDICINE. 1978. p. 700–700.
• Zalutsky MR, Friedman AM, Buckingham FC. Synthesis of a non labile astatine protein conjugate. Journal of Labelled Compounds and Radiopharmaceuticals. 1977 Dec 1;13(2):181–2.
• Zalutsky MR, Rayudu GV, Friedman AM. The biological behavior of tin following administration of nine 99mTc-Sn complexes. Int J Nucl Med Biol. 1977 Dec;4(3–4):224–30.
• Friedman AM, Zalutsky MR, Wung W, Buckingham F, Scherr GH, Wainer B, et al. Preparation of a biologically stable and immunogenically competent astatinated protein. Int J Nucl Med Biol. 1977 Dec;4(3–4):219–24.
• Zalutsky MR, Friedman AM, Sullivan JC, Ruby SL, Rayudu GV. Studies of tumor metabolism--II. Mössbauer spectroscopy of 57Co-bleomycin. Int J Nucl Med Biol. 1977 Dec;4(3–4):216–8.
• Zalutsky M, Sullivan JC, Friedman AM, Rayudu GV, Deutsch E. Organ distribution of 99mTc-labelled aminethiols. Int J Nucl Med Biol. 1977 Jan;4(1):53–6.
• Zalutsky MR, MacIas ES, Meyer RA. Structure of N=81 nuclei: Levels of Nd141 and Ce139 populated in beta decay. Physical Review C. 1976 Jan 1;13(4):1590–600.
• Zalutsky MR, MacIas ES. Angular correlation of x rays: L-M cascades of plutonium. Physical Review A. 1975 Jan 1;12(2):526–30.
• Zalutsky MR, Macias ES. Comparison of techniques for the determination of the L2-L3X Coster-Kronig transition probability. Physical Review A. 1975 Jan 1;11(3):1093–6.
• Zalutsky MR, Macias ES. Experimental determination of the L2-L3X Coster-Kronig transition probability in europium, plutonium, and curium. Physical Review A. 1975 Jan 1;11(1):71–4.
• Zalutsky MR, Macias ES, Catz AL. Angular correlation between K and L x rays in tantalum. Physical Review A. 1975 Jan 1;11(1):75–8.
• Zalutsky MR, MacIas ES. Search for an anisotropy between Ll x rays and γ rays in the decay of Cm243. Physical Review C. 1975 Jan 1;12(3):1076–9.
• Zalutsky MR, Macias ES. Decay of 5.8-min Pmm140 and 10-sec Pmg140 to levels of Nd140. Physical Review C. 1975 Jan 1;12(3):997–1002.
• Zalutsky MR, Macias ES. Measurement of the angular correlation between L-M X-ray cascades. Physics Letters A. 1974 Sep 23;49(4):285–6.
• Macias ES, Zalutsky MR. K-L X-ray angular correlations in Cm, Pu and Eu. Phys Rev A, Gen Phys (USA). 1974;9(6):2356–64.
• Macias ES, Head RE, Hseuh HC, Zalutsky MR. On-line determination of transport time of a helium-jet system. Nucl Instrum Methods (Netherlands). 1974;122(3):365–8.
• Macias ES, Head RE, Hseuh HC, Zalutsky MR. On-line determination of transport time of a helium-jet system. Nuclear Instruments and Methods. 1974 Jan 1;122(C):365–8.
• Boskovitz A, Reardon DA, Wikstrand CJ, Zalutsky MR, Bigner DD. Monoclonal Antibodies. In: Current Clinical Oncology. Humana Press; p. 373–89.
• Zalutsky MR, Macias ES. Measurement of the angular correlation between L-M X-ray cascades. Phys Lett A (Netherlands). 49A(4):285–6.